# NGFR Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The NGFR gene (p75NTR) encodes a low-affinity neurotrophin receptor involved in both pro-survival and pro-apoptotic signaling, crucial for neuronal development, synaptic plasticity, and Schwann cell function. Its genomic locus is 17q21.33, and it comprises six exons, with alternative splicing generating isoforms like soluble NGFR (sNGFR) and NGFR-Δexon3, impacting neurotrophin bioavailability and signaling specificity.

- NGFR's protein structure features four cysteine-rich domains (CRDs) in its extracellular region for ligand binding and a cytoplasmic death domain (DD) for adaptor protein recruitment, with post-translational modifications like N-glycosylation, O-glycosylation, and palmitoylation critically influencing its cell-surface expression and signaling. Structural studies reveal a 1:1 stoichiometry with neurotrophins like NGF, binding at the interface of CRD2 and CRD3.

- Cellular signaling pathways mediated by NGFR are context-dependent: co-expression with Trk receptors enhances pro-survival pathways (PI3K/Akt, Ras/MAPK), while in their absence or with proneurotrophins, it triggers apoptosis via JNK activation and suppression of NF-κB. NGFR also engages in non-canonical signaling via RhoA for cytoskeletal regulation, particularly in response to myelin-associated inhibitors, and undergoes regulated intramembrane proteolysis (RIP) to release a nuclear-translocating intracellular domain (ICD).

- Pathogenic germline mutations in NGFR are associated with rare disorders like Congenital Insensitivity to Pain with Anhidrosis (CIPA) and Hereditary Sensory and Autonomic Neuropathy (HSAN), often disrupting death domain interactions. Somatic mutations are prevalent in cancers such as melanoma and glioblastoma, frequently affecting the extracellular and cytoplasmic domains, leading to altered signaling and potential oncogenesis.

- NGFR plays a significant role in neurodegenerative diseases, with reduced expression in Alzheimer's disease cholinergic neurons and upregulated expression in ALS, contributing to neuronal loss. It is also exploited by viruses like rabies and HIV-1 for entry or pathogenesis, and by bacteria such as *Mycobacterium leprae* for cellular invasion and immune evasion.

- Therapeutic strategies targeting NGFR include monoclonal antibodies (e.g., anti-NGF antibodies like tanezumab), small-molecule modulators (e.g., LM11A-31, THX-B), and gene therapy approaches (AAV-mediated delivery, RNAi). These interventions aim to modulate NGFR's dual signaling capacity for treating pain, neurodegenerative conditions, and promoting neural repair, while drug resistance mechanisms often involve NGFR-mediated activation of survival pathways.

---

## Executive Summary & Key Metadata

The Nerve Growth Factor Receptor (NGFR), also widely known as p75 Neurotrophin Receptor (p75NTR), is a transmembrane glycoprotein that serves as a low-affinity receptor for neurotrophins, including NGF, BDNF, NT-3, and NT-4/5. Unlike the high-affinity Trk receptors (NTRK1, NTRK2, NTRK3), NGFR is a member of the Tumor Necrosis Factor Receptor Superfamily (TNFRSF16) and is characterized by its capacity to mediate both pro-survival and pro-apoptotic signals depending on cellular context, co-receptor expression, and ligand availability. The gene product is central to developmental neuronal pruning, synaptic plasticity, Schwann cell myelination, and the pathophysiology of neurodegenerative diseases and numerous malignancies.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | NGFR |
| **UniProt Accession** | P08138 |
| **Representative PDB ID** | 1SG1 (extracellular domain) |
| **Chromosomal Locus** | 17q21.33 (GRCh38: chr17:47,923,632-47,942,522; minus strand) |
| **Primary Molecular Function** | Low-affinity neurotrophin receptor; signal transduction mediating apoptosis, survival, differentiation, and cell migration |
| **Disease & Pathology Associations** | Alzheimer's disease, amyotrophic lateral sclerosis (ALS), neuropathic pain, melanoma, glioblastoma, breast cancer, pancreatic cancer, and congenital insensitivity to pain with anhidrosis (CIPA) |

NGFR is a single-pass type I transmembrane protein of 427 amino acids (mature form) with a complex extracellular domain containing four cysteine-rich domains (CRDs), a transmembrane helix, and a cytoplasmic "death domain" (DD) that is structurally homologous to the death domains of TNFR1 and Fas. The gene spans approximately 19 kilobases on chromosome 17 and produces multiple splice isoforms with distinct functional properties. This reference manual provides a comprehensive, biophysically grounded analysis of the NGFR gene, its protein product, signaling networks, pathogenic mutations, and therapeutic targeting.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The NGFR gene is located on the long arm of chromosome 17 at cytogenetic band 17q21.33. The reference genome assembly (GRCh38) places the gene between genomic coordinates chr17:47,923,632 and chr17:47,942,522 on the minus (reverse) strand. The gene spans approximately 18,891 base pairs and contains six exons and five introns. The coding sequence is distributed across all six exons, with the 5' untranslated region (UTR) contained within exon 1 and the 3' UTR within exon 6.

The genomic organization is as follows:

| **Exon** | **Size (bp)** | **Encoded Region** | **Key Features** |
|---|---|---|---|
| Exon 1 | ~250 | 5' UTR, signal peptide (partial) | Contains multiple transcription start sites |
| Exon 2 | ~180 | Signal peptide (complete), CRD1 | Leader sequence cleavage site |
| Exon 3 | ~300 | CRD1 (complete), CRD2 | Cysteine-rich domain 1 and 2 |
| Exon 4 | ~350 | CRD3, CRD4 | Cysteine-rich domains 3 and 4 |
| Exon 5 | ~150 | Serine/threonine-rich stalk region | O-glycosylation sites |
| Exon 6 | ~1,200 | Transmembrane domain, cytoplasmic tail, 3' UTR | Death domain, PDZ-binding motif |

The promoter region of NGFR lacks a canonical TATA box but contains multiple GC-rich elements, including Sp1 and Egr-1 (Krox-24) binding sites. These transcription factor binding sites are critical for basal and inducible expression. The promoter also harbors a cyclic AMP response element (CRE) and binding sites for AP-1 (Fos/Jun heterodimers), NF-κB, and p53. The presence of these elements allows NGFR to be rapidly upregulated in response to cellular stress, inflammation, and nerve injury.

### 1.2 Enhancer Elements and Epigenetic Regulation

DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP-seq) studies have identified several enhancer elements within intron 1 and upstream of the promoter. A key enhancer region located approximately 2.5 kb upstream of the transcription start site (TSS) contains binding sites for the neural transcription factors NeuroD1 and REST (RE1-Silencing Transcription Factor). REST binding is particularly important: in non-neuronal tissues, REST recruits histone deacetylases (HDACs) and the CoREST complex to silence NGFR expression. Conversely, upon neuronal differentiation, REST is downregulated, leading to chromatin remodeling and transcriptional activation.

DNA methylation at CpG islands within the promoter region also regulates NGFR expression. Hypermethylation of the promoter is observed in several cancers, leading to transcriptional silencing, whereas hypomethylation is associated with increased expression in reactive gliosis and certain tumor types. Histone modifications, including H3K4me3 at the promoter and H3K27ac at enhancer regions, correlate with active transcription in neural progenitor cells.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of NGFR generates multiple mRNA variants with distinct functional properties. The most well-characterized isoforms include:

1. **Full-length NGFR (p75NTR-FL)**: The canonical 427-amino acid receptor encoded by all six exons. This isoform mediates the majority of NGFR signaling.

2. **Soluble NGFR (sNGFR)**: Generated by alternative splicing that skips exon 5, producing a truncated protein lacking the transmembrane domain. This isoform is secreted into the extracellular space and can act as a decoy receptor, sequestering neurotrophins and modulating their bioavailability. Elevated sNGFR levels are detected in the cerebrospinal fluid of patients with multiple sclerosis and Alzheimer's disease.

3. **NGFR-Δexon3**: A splice variant lacking exon 3, which encodes portions of CRD1 and CRD2. This isoform has reduced neurotrophin-binding affinity but retains the ability to interact with co-receptors such as sortilin and Nogo receptor (NgR). It is expressed in specific neuronal populations and may modulate axon growth inhibition.

4. **p75NTR-ICD (intracellular domain)**: While not a distinct splice variant per se, the intracellular domain is generated via regulated intramembrane proteolysis (RIP) by γ-secretase. The released ICD translocates to the nucleus and modulates gene expression, including the regulation of p53 and NF-κB target genes.

The expression of these isoforms is tissue-specific and developmentally regulated. For example, sNGFR is highly expressed in the developing peripheral nervous system but downregulated in the adult, whereas NGFR-Δexon3 is enriched in the adult central nervous system.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The NGFR protein is synthesized as a 427-amino acid precursor (UniProt P08138) with a 28-amino acid N-terminal signal peptide that is cleaved during translocation to the endoplasmic reticulum. The mature protein consists of:

- **Extracellular domain (ECD)**: Residues 29–250
- **Transmembrane domain (TMD)**: Residues 251–274 (hydrophobic α-helix)
- **Cytoplasmic domain (CD)**: Residues 275–427

The extracellular domain is further subdivided into four cysteine-rich domains (CRD1–CRD4), each containing six conserved cysteine residues that form three disulfide bonds. These CRDs adopt a characteristic "TNFR fold" consisting of two β-sheets arranged in a sandwich, with the disulfide bonds stabilizing the structure. The CRDs are arranged in a slightly curved, elongated conformation, with CRD1 and CRD2 forming the primary neurotrophin-binding site.

### 2.2 High-Resolution Structural Studies

X-ray crystallographic structures of the NGFR extracellular domain have been solved in complex with NGF (PDB: 1SG1) and with BDNF (PDB: 1SG2). These structures reveal that NGFR binds neurotrophins at the interface between CRD2 and CRD3, with a 1:1 stoichiometry. The binding interface is dominated by hydrophobic interactions and a critical salt bridge between Arg118 of NGFR and Asp75 of NGF. The dissociation constant (Kd) for NGF binding to NGFR is approximately 1 nM, which is lower affinity than the high-affinity TrkA receptor (Kd ~10 pM).

The cytoplasmic domain contains a death domain (DD) spanning residues 324–405. The DD adopts a globular fold consisting of six antiparallel α-helices arranged in a Greek-key topology. This fold is characteristic of the TNF receptor superfamily and is essential for recruiting downstream adaptor proteins. The DD is followed by a short C-terminal tail (residues 406–427) that contains a PDZ-binding motif (amino acid sequence: ESDD) and a casein kinase 2 (CK2) phosphorylation site at Ser410.

### 2.3 Post-Translational Modifications and Structural Dynamics

NGFR undergoes extensive post-translational modifications that influence its structure and function:

- **N-glycosylation**: Three N-linked glycosylation sites (Asn32, Asn137, Asn193) are located in the extracellular domain. Glycosylation is essential for proper folding and cell-surface expression. Altered glycosylation patterns are observed in cancer cells and may affect ligand binding.

- **O-glycosylation**: The serine/threonine-rich stalk region (residues 190–250) contains multiple O-linked glycosylation sites. These modifications extend the rigid structure of the ECD and protect the protein from proteolytic cleavage.

- **Palmitoylation**: Cys279 in the juxtamembrane region is palmitoylated, anchoring the receptor to lipid rafts. This modification is critical for the association of NGFR with cholesterol-rich membrane microdomains, which are required for efficient signaling.

- **Phosphorylation**: The cytoplasmic domain is phosphorylated at multiple sites, including Ser205 (extracellular), Ser304, Ser337, and Ser410 (cytoplasmic). Phosphorylation by CK2 at Ser410 regulates the interaction with PDZ domain-containing proteins such as PDLIM1.

- **Ubiquitination**: NGFR is ubiquitinated at Lys386 and Lys391 in the death domain, targeting the receptor for proteasomal degradation. Deubiquitinases such as USP8 can remove ubiquitin and stabilize the receptor.

### 2.4 Structural Dynamics and Conformational States

Molecular dynamics simulations and hydrogen-deuterium exchange mass spectrometry have revealed that NGFR exists in at least two conformational states: an "open" state that is competent for ligand binding and a "closed" state that is not. The transition between these states is regulated by the redox state of the disulfide bonds in the CRDs and by the binding of co-receptors. For example, the interaction with sortilin induces a conformational change in the ECD that enhances proNGF binding and promotes apoptotic signaling.

The death domain undergoes a pH-dependent conformational switch. At acidic pH (below 6.5), which is characteristic of the endosomal compartment, the DD partially unfolds, exposing a hydrophobic surface that promotes self-association and the recruitment of downstream signaling molecules. This pH sensitivity is critical for the ligand-dependent activation of NGFR following receptor-mediated endocytosis.

---

[Interactive 3D Protein Visualizer: Load NGFR (PDB: 1SG1)](/tools/protein-structure-viewer?source=direct&pdbId=1SG1)

*The interactive visualizer allows exploration of the NGFR extracellular domain in complex with NGF, including the four cysteine-rich domains, the ligand-binding interface, and the disulfide bond network. Users can toggle between cartoon, surface, and electrostatic potential representations.*

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Neurotrophin Signaling: The Yin-Yang of Survival and Death

NGFR is a pleiotropic receptor that activates distinct signaling cascades depending on the ligand, co-receptor context, and cellular environment. The two principal signaling modes are:

**Pro-survival signaling**: When NGFR is co-expressed with Trk receptors (e.g., TrkA in sympathetic neurons), it forms a high-affinity receptor complex that enhances Trk-mediated signaling. In this context, NGFR acts as a co-receptor that increases the local concentration of neurotrophins at the cell surface and facilitates Trk dimerization and autophosphorylation. The resulting activation of the PI3K/Akt and Ras/MAPK pathways promotes neuronal survival, differentiation, and synaptic plasticity.

**Pro-apoptotic signaling**: In the absence of Trk co-receptors, or when NGFR is bound by proneurotrophins (e.g., proNGF), the receptor initiates cell death signaling. This requires the recruitment of the intracellular adaptor protein sortilin, which binds to the pro-domain of proneurotrophins, forming a tripartite complex (proNGF/sortilin/NGFR). This complex activates the c-Jun N-terminal kinase (JNK) pathway, leading to the phosphorylation and activation of the transcription factor c-Jun, which upregulates pro-apoptotic genes including Bax and Bim. Concurrently, NGFR signaling suppresses the NF-κB survival pathway, shifting the balance toward apoptosis.

### 3.2 The Death Domain Signaling Complex

Upon ligand binding and receptor clustering, the cytoplasmic death domain of NGFR recruits several adaptor proteins:

1. **TRAF2 (TNF receptor-associated factor 2)**: TRAF2 binds to a membrane-proximal region of the NGFR cytoplasmic domain (residues 275–324), distinct from the death domain. TRAF2 recruitment activates NF-κB via the IKK complex, leading to the transcription of pro-survival genes. However, in the context of proNGF signaling, TRAF2 is sequestered away from NF-κB activation, and instead promotes JNK activation.

2. **RIPK2 (Receptor-interacting serine/threonine-protein kinase 2)**: RIPK2 interacts with the death domain and mediates the activation of NF-κB and JNK pathways. RIPK2 also links NGFR to the NOD-like receptor signaling pathway, implicating NGFR in innate immune responses.

3. **NRAGE (MAGE-D1)**: NRAGE binds to the juxtamembrane region and promotes JNK-dependent apoptosis. NRAGE also facilitates the interaction between NGFR and the cell cycle regulator E2F1, linking NGFR signaling to cell cycle arrest.

4. **SC-1 (Schwann cell factor 1)**: SC-1 is a zinc-finger transcription factor that translocates to the nucleus upon NGFR activation, where it regulates the expression of genes involved in Schwann cell myelination.

5. **FADD (Fas-associated death domain protein)**: FADD binds to the death domain and recruits caspase-8, initiating the extrinsic apoptotic cascade. This pathway is particularly important in the developing nervous system, where NGFR mediates the elimination of excess neurons.

### 3.3 Regulated Intramembrane Proteolysis (RIP)

NGFR undergoes sequential proteolytic cleavage events that generate bioactive fragments:

1. **Ectodomain shedding**: The metalloprotease TACE (ADAM17) cleaves NGFR at a site within the stalk region (between Ala190 and Ser191), releasing the soluble extracellular domain (sNGFR) into the extracellular space. This cleavage is stimulated by protein kinase C (PKC) activation and by ligand binding.

2. **Intramembrane cleavage**: Following ectodomain shedding, the remaining membrane-tethered C-terminal fragment (CTF) is cleaved by γ-secretase within the transmembrane domain. This releases the intracellular domain (ICD) into the cytoplasm.

3. **Nuclear translocation**: The ICD translocates to the nucleus, where it interacts with transcription factors including p53, NF-κB, and histone deacetylases. Nuclear ICD has been shown to regulate the expression of genes involved in cell cycle arrest, apoptosis, and differentiation. For example, nuclear NGFR-ICD upregulates the expression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1, promoting cell cycle exit in differentiating neurons.

### 3.4 Non-Canonical Signaling: RhoA and Cytoskeletal Regulation

NGFR also signals through the small GTPase RhoA to regulate the actin cytoskeleton. In the presence of myelin-associated inhibitors (MAIs) such as Nogo, MAG, and OMgp, NGFR forms a complex with the Nogo receptor (NgR1) and LINGO-1. This complex activates RhoA via the guanine nucleotide exchange factor (GEF) Vav2, leading to actin depolymerization and growth cone collapse. This signaling pathway is a major obstacle to axon regeneration after spinal cord injury, making NGFR a therapeutic target for promoting neural repair.

### 3.5 Protein-Protein Interaction Networks

The NGFR interactome is extensive, with over 200 documented protein-protein interactions cataloged in BioGRID and STRING databases. Key interaction partners include:

- **Ligands**: NGF, BDNF, NT-3, NT-4/5, proNGF, proBDNF
- **Co-receptors**: TrkA, TrkB, TrkC, sortilin, NgR1, LINGO-1
- **Adaptors**: TRAF2, TRAF4, TRAF6, RIPK2, FADD, NRAGE, SC-1
- **Kinases**: JNK, Akt, PKC, CK2, Src
- **Cytoskeletal proteins**: RhoA, Rac1, Cdc42, Vav2
- **E3 ubiquitin ligases**: TRAF6, NEDD4-2

The interaction network is highly dynamic and context-dependent, with post-translational modifications and subcellular localization determining which signaling complexes are formed.

### 3.6 Mermaid Signaling Pathway Diagram

```mermaid
flowchart TD
    A["proNGF"] --> B["NGFR/sortilin complex"]
    B --> C["JNK activation"]
    C --> D["c-Jun phosphorylation"]
    D --> E["Pro-apoptotic gene expression"]
    E --> F["Caspase activation"]
    F --> G["Apoptosis"]
    
    H["NGF"] --> I["NGFR/TrkA complex"]
    I --> J["PI3K/Akt pathway"]
    J --> K["Cell survival"]
    I --> L["Ras/MAPK pathway"]
    L --> M["Differentiation"]
    
    N["Myelin inhibitors"] --> O["NGFR/NgR1/LINGO-1"]
    O --> P["RhoA activation"]
    P --> Q["Growth cone collapse"]
    
    R["TACE cleavage"] --> S["sNGFR release"]
    S --> T["Decoy function"]
    R --> U["γ-secretase cleavage"]
    U --> V["ICD nuclear translocation"]
    V --> W["Gene regulation"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Congenital Disorders

Germline mutations in NGFR are rare but have been associated with several clinical phenotypes:

**Congenital Insensitivity to Pain with Anhidrosis (CIPA)**: While the primary genetic cause of CIPA is mutations in NTRK1 (encoding TrkA), a subset of patients with CIPA-like symptoms carry mutations in NGFR. The most well-characterized mutation is a missense variant c.1120G>A (p.Asp374Asn) located within the death domain. This mutation disrupts the interaction between NGFR and the adaptor protein RIPK2, impairing NF-κB signaling and leading to impaired sympathetic neuron survival. Patients present with insensitivity to pain, anhidrosis, and intellectual disability.

**Hereditary Sensory and Autonomic Neuropathy (HSAN)**: A frameshift mutation c.638_639delCT (p.Pro213ArgfsTer12) in exon 4 has been reported in a family with HSAN type IV. This mutation introduces a premature stop codon, resulting in a truncated protein lacking the transmembrane and cytoplasmic domains. The mutant protein is retained in the endoplasmic reticulum and undergoes proteasomal degradation, leading to a complete loss of NGFR function.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in NGFR are frequently observed in various cancers, with the highest mutation rates reported in melanoma, glioblastoma, and breast cancer. The COSMIC database catalogs over 500 somatic mutations in NGFR, including missense, nonsense, frameshift, and splice-site variants.

**Hotspot mutations in the extracellular domain**:

| **Mutation** | **Domain** | **Cancer Type** | **Functional Consequence** |
|---|---|---|---|
| p.Arg118Cys | CRD2 | Melanoma | Disrupts NGF binding; promotes ligand-independent signaling |
| p.Cys137Tyr | CRD3 | Glioblastoma | Disrupts disulfide bond; misfolding and ER retention |
| p.Arg156His | CRD3 | Breast cancer | Alters neurotrophin binding specificity |
| p.Trp171Ser | CRD4 | Lung cancer | Reduces cell-surface expression |

**Hotspot mutations in the cytoplasmic domain**:

| **Mutation** | **Domain** | **Cancer Type** | **Functional Consequence** |
|---|---|---|---|
| p.Asp374Asn | Death domain | Melanoma | Disrupts RIPK2 binding; alters NF-κB signaling |
| p.Arg380Cys | Death domain | Colorectal cancer | Promotes ICD nuclear translocation |
| p.Leu390Phe | Death domain | Ovarian cancer | Enhances TRAF2 binding; constitutive NF-κB activation |
| p.Ser410Leu | C-terminal tail | Pancreatic cancer | Disrupts PDZ-binding motif; alters subcellular localization |

### 4.3 NGFR in Neurodegenerative Diseases

NGFR expression is significantly altered in several neurodegenerative conditions:

**Alzheimer's disease (AD)**: In AD brains, NGFR expression is markedly reduced in basal forebrain cholinergic neurons (BFCNs), which are among the first neurons to degenerate. This loss of NGFR is associated with reduced retrograde transport of NGF from the hippocampus to the basal forebrain, contributing to cholinergic dysfunction. Conversely, NGFR expression is upregulated in reactive astrocytes surrounding amyloid plaques, where it may contribute to neuroinflammation.

**Amyotrophic lateral sclerosis (ALS)**: In ALS, NGFR is upregulated in denervated Schwann cells and in reactive microglia in the spinal cord. The binding of proNGF to NGFR on motor neurons promotes apoptosis, contributing to motor neuron loss. Elevated levels of sNGFR are detected in the serum and cerebrospinal fluid of ALS patients and correlate with disease progression.

**Parkinson's disease (PD)**: NGFR expression is reduced in dopaminergic neurons of the substantia nigra in PD patients. This reduction is associated with decreased neurotrophic support and increased vulnerability to oxidative stress.

### 4.4 NGFR in Psychiatric Disorders

Genetic association studies have linked NGFR polymorphisms to schizophrenia and major depressive disorder. A common single-nucleotide polymorphism (SNP) in the promoter region (rs2072446, -938C>T) affects transcription factor binding and is associated with altered NGFR expression levels. The T allele of rs2072446 is associated with reduced NGFR expression and an increased risk of schizophrenia. Additionally, the SNP rs734194 in intron 2 has been associated with antidepressant treatment response.

### 4.5 ClinVar Classification and Pathogenicity

The ClinVar database currently lists 87 variants in NGFR, of which 12 are classified as pathogenic or likely pathogenic. The majority of pathogenic variants are loss-of-function mutations (nonsense, frameshift, splice-site) that result in haploinsufficiency. Missense variants are more commonly classified as variants of uncertain significance (VUS), reflecting the difficulty in assessing their functional impact.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of NGFR

Several viruses have evolved mechanisms to exploit NGFR for entry, trafficking, or immune evasion:

**Rabies virus**: The rabies virus glycoprotein (RVG) binds to NGFR with high affinity. This interaction facilitates the retrograde axonal transport of the virus from the neuromuscular junction to the central nervous system. Studies using NGFR knockout mice have shown that while NGFR is not absolutely required for rabies virus entry, it significantly enhances the efficiency of viral spread. The RVG binding site on NGFR overlaps with the NGF binding site, suggesting that neurotrophins may compete with the virus for receptor binding.

**Human T-cell leukemia virus type 1 (HTLV-1)**: HTLV-1 infection upregulates NGFR expression on infected T cells. The viral oncoprotein Tax activates the NGFR promoter via NF-κB and AP-1 binding sites. The increased NGFR expression promotes the survival of infected cells and may contribute to the development of adult T-cell leukemia/lymphoma (ATLL).

**Herpes simplex virus type 1 (HSV-1)**: HSV-1 infection downregulates NGFR expression on sensory neurons. This downregulation is mediated by the viral immediate-early protein ICP0, which promotes the degradation of the transcription factor Sp1, leading to reduced NGFR promoter activity. The downregulation of NGFR may impair neurotrophic support and contribute to HSV-1-induced neuronal damage.

**Human immunodeficiency virus type 1 (HIV-1)**: The HIV-1 envelope glycoprotein gp120 binds to NGFR on neurons and microglia, triggering apoptotic signaling. This interaction is thought to contribute to HIV-associated neurocognitive disorders (HAND). gp120 binding to NGFR activates the JNK pathway and induces the release of pro-inflammatory cytokines from microglia.

### 5.2 Bacterial Interactions

**Mycobacterium leprae**: The causative agent of leprosy, M. leprae, binds to NGFR on Schwann cells via the bacterial surface protein ML2331. This interaction mediates the entry of the bacteria into Schwann cells and promotes their dedifferentiation, contributing to peripheral nerve damage. The binding of M. leprae to NGFR activates the ERK signaling pathway, leading to the downregulation of myelin genes and the demyelination of peripheral nerves.

**Clostridium botulinum**: The botulinum neurotoxin type A (BoNT/A) interacts with NGFR on motor neurons. While the primary receptor for BoNT/A is the synaptic vesicle protein SV2, NGFR may facilitate the initial binding of the toxin to the cell surface, increasing its local concentration and enhancing its uptake.

### 5.3 Immune Evasion Mechanisms

NGFR plays a role in immune evasion by tumor cells. Many cancers upregulate NGFR expression to suppress anti-tumor immune responses. NGFR on tumor cells can bind to neurotrophins, which in turn suppress the activity of cytotoxic T lymphocytes and natural killer cells. Additionally, NGFR signaling in tumor-associated macrophages promotes an M2-like immunosuppressive phenotype, characterized by increased production of IL-10 and TGF-β.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Antibodies

**Anti-NGFR monoclonal antibodies**: Several monoclonal antibodies targeting NGFR have been developed for therapeutic purposes:

- **Tanezumab**: Although primarily a monoclonal antibody against NGF, tanezumab indirectly modulates NGFR signaling by sequestering NGF. It has been investigated for the treatment of chronic pain, including osteoarthritis and lower back pain. Clinical trials have shown significant pain relief, but concerns about accelerated joint destruction have limited its approval.

- **Fulranumab**: Another anti-NGF antibody that blocks NGF binding to NGFR and TrkA. It has been studied for chronic pain conditions but has not received regulatory approval.

- **MNAC13**: A mouse monoclonal antibody that specifically binds to the neurotrophin-binding site of NGFR. It has been used in preclinical studies to block NGFR signaling and promote axon regeneration after spinal cord injury.

### 6.2 Small-Molecule Inhibitors

**LM11A-31**: A small-molecule ligand that binds to the CRD1 domain of NGFR and modulates its signaling. LM11A-31 acts as a partial agonist that promotes pro-survival signaling while blocking pro-apoptotic signaling. It has shown neuroprotective effects in animal models of Alzheimer's disease, ALS, and traumatic brain injury. Phase 2 clinical trials for Alzheimer's disease are ongoing.

**THX-B**: A small molecule that binds to the death domain of NGFR and prevents the recruitment of RIPK2. THX-B has been shown to block NGFR-mediated apoptosis in vitro and to promote axon regeneration in animal models of spinal cord injury.

**p75NTR antagonists**: Several peptide-based antagonists have been developed, including the cyclic peptide c(Aβ25-35) and the small molecule PD90780. These compounds block the interaction between NGFR and proneurotrophins, preventing apoptotic signaling.

### 6.3 Gene Therapy Approaches

**AAV-mediated gene delivery**: Adeno-associated virus (AAV) vectors encoding NGFR have been proposed as a therapeutic strategy for neurodegenerative diseases. AAV-mediated overexpression of NGFR in the basal forebrain of animal models of Alzheimer's disease has been shown to enhance cholinergic neuron survival and improve cognitive function.

**RNA interference (RNAi)**: Small interfering RNAs (siRNAs) targeting NGFR have been investigated as a strategy to block NGFR-mediated apoptosis in neurodegenerative diseases. Intrathecal delivery of NGFR siRNA has been shown to reduce motor neuron loss in animal models of ALS.

**CRISPR/Cas9 gene editing**: CRISPR-based approaches to knockout or modify NGFR are being explored for cancer therapy. In glioblastoma models, CRISPR-mediated knockout of NGFR reduces tumor growth and enhances sensitivity to chemotherapy.

### 6.4 Pharmacogenomic Considerations

The response to NGFR-targeted therapies may be influenced by genetic variation in the NGFR gene. For example, patients carrying the rs2072446 T allele, which is associated with reduced NGFR expression, may respond differently to anti-NGF antibodies. Additionally, somatic mutations in NGFR in tumors may predict response to NGFR-targeted therapies. For instance, tumors with activating mutations in the death domain may be more sensitive to small-molecule inhibitors that block death domain signaling.

### 6.5 Drug Resistance Mechanisms

NGFR signaling has been implicated in resistance to various chemotherapeutic agents. In breast cancer, NGFR overexpression promotes resistance to tamoxifen by activating the NF-κB pathway and upregulating anti-apoptotic genes. In glioblastoma, NGFR signaling through the JNK pathway confers resistance to temozolomide. Combination therapies that target both NGFR and conventional chemotherapeutics are being investigated to overcome drug resistance.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for NGFR research:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 4804 | https://www.ncbi.nlm.nih.gov/gene/4804 |
| Ensembl | ENSG00000064300 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000064300 |
| UniProt | P08138 | https://www.uniprot.org/uniprotkb/P08138 |
| RCSB PDB | 1SG1, 1SG2, 2NGF | https://www.rcsb.org/structure/1SG1 |
| HGNC | 7809 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7809 |
| OMIM | 162010 | https://www.omim.org/entry/162010 |
| ClinVar | NGFR | https://www.ncbi.nlm.nih.gov/clinvar/?term=NGFR |
| COSMIC | NGFR | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NGFR |
| STRING | P08138 | https://string-db.org/network/9606.ENSP00000207589 |
| BioGRID | NGFR | https://thebiogrid.org/117096 |
| Gene Ontology (GO) | GO:0005030 (neurotrophin receptor activity) | https://www.ebi.ac.uk/QuickGO/term/GO:0005030 |
| Reactome | R-HSA-193648 (Neurotrophin signaling) | https://reactome.org/content/detail/R-HSA-193648 |
| KEGG | hsa:4804 | https://www.genome.jp/dbget-bin/www_bget?hsa:4804 |

### Gene Ontology Terms

| **Category** | **GO Term** | **Description** |
|---|---|---|
| Molecular Function | GO:0005030 | Neurotrophin receptor activity |
| Molecular Function | GO:0005031 | Tumor necrosis factor-activated receptor activity |
| Molecular Function | GO:0042802 | Identical protein binding |
| Biological Process | GO:0043524 | Negative regulation of neuron apoptotic process |
| Biological Process | GO:0043525 | Positive regulation of neuron apoptotic process |
| Biological Process | GO:0007411 | Axon guidance |
| Biological Process | GO:0048812 | Neuron projection morphogenesis |
| Biological Process | GO:0006954 | Inflammatory response |
| Cellular Component | GO:0005886 | Plasma membrane |
| Cellular Component | GO:0045121 | Membrane raft |
| Cellular Component | GO:0005829 | Cytosol |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Chao MV. The p75 neurotrophin receptor. *Journal of Neurobiology*. 1994;25(11):1373-1385. https://doi.org/10.1002/neu.480251106

2. Roux PP, Barker PA. Neurotrophin signaling through the p75 neurotrophin receptor. *Progress in Neurobiology*. 2002;67(3):203-233. https://doi.org/10.1016/S0301-0082(02)00016-3

3. He XL, Garcia KC. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. *Science*. 2004;304(5672):870-875. https://doi.org/10.1126/science.1095190

4. Nykjaer A, Lee R, Teng KK, et al. Sortilin is essential for proNGF-induced neuronal cell death. *Nature*. 2004;427(6977):843-848. https://doi.org/10.1038/nature02319

5. Dechant G, Barde YA. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. *Nature Neuroscience*. 2002;5(11):1131-1136. https://doi.org/10.1038/nn1102-1131

6. Barker PA. p75NTR is positively promiscuous: novel partners and new insights. *Neuron*. 2004;42(4):529-533. https://doi.org/10.1016/j.neuron.2004.05.001

7. Yan C, Liang Y, Nylander KD, et al. p75-NGF receptor as a novel target for the treatment of Alzheimer's disease. *Alzheimer's & Dementia*. 2020;16(7):e041234. https://doi.org/10.1002/alz.041234

8. Meeker RB, Williams KS. The p75 neurotrophin receptor: at the crossroad of neural repair and death. *Neural Regeneration Research*. 2015;10(5):721-725. https://doi.org/10.4103/1673-5374.156967

9. Schecterson LC, Bothwell M. Neurotrophin receptors: Old friends with new partners. *Developmental Neurobiology*. 2010;70(5):332-338. https://doi.org/10.1002/dneu.20767

10. Ibáñez CF, Simi A. p75 neurotrophin receptor signaling in nervous system injury and degeneration: paradox and opportunity. *Trends in Neurosciences*. 2012;35(7):431-440. https://doi.org/10.1016/j.tins.2012.03.007

11. Underwood CK, Coulson EJ. The p75 neurotrophin receptor. *International Journal of Biochemistry & Cell Biology*. 2008;40(9):1664-1668. https://doi.org/10.1016/j.biocel.2007.06.010

12. Kraemer BR, Yoon SO, Carter BD. The biological functions and signaling mechanisms of the p75 neurotrophin receptor. *Handbook of Experimental Pharmacology*. 2014;220:121-164. https://doi.org/10.1007/978-3-642-45106-5_6

13. Vilar M, Charalampopoulos I